Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits

Academic Article

Abstract

  • Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors. © 1989.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Potter ME; Partridge EE; Shingleton HM; Soong SJ; Kim RY; Hatch KD; Austin JM
  • Start Page

  • 314
  • End Page

  • 318
  • Volume

  • 32
  • Issue

  • 3